Nivolumab and Sunitinib in Patients with Advanced Bone Sarcomas: A Multicenter, Single-Arm, Phase 2 Trial.
CANCER(2025)
Key words
anti-angiogeninic,bone,dedifferentiated chondrosarcoma,Ewing sarcoma,immunotherapy,nivolumab,osteosarcoma,PD-L1 inhibitor,sarcoma,sunitinib
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined